Publications - IR Sant Pau

Search

01/08/2025 Fibrosis quantification in hidradenitis suppurativa tunnels: Histological correlation with shear wave elastography

Mateu-Arrom, L, Mozos, A, Puig, L, Vilarrasa, E. Fibrosis quantification in hidradenitis suppurativa tunnels: Histological correlation with shear wave elastography. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(8)DOI:10.1111/jdv.20514. PMID:39699957. IF:8.000(Q1/1D).

22/03/2025 SSX and SS18-SSX Antibodies as Additional Tools for Diagnosing Undifferentiated Neoplasms With the EWSR1::SSX3 Fusion

Machado, I, Llombart-Bosch, A, Fumagalli, C, Antonescu, CR. SSX and SS18-SSX Antibodies as Additional Tools for Diagnosing Undifferentiated Neoplasms With the EWSR1::SSX3 Fusion. GENES CHROMOSOMES & CANCER. 2025; 64(3)DOI:10.1002/gcc.70044. PMID:40119747. IF:2.800(Q2/5D).

01/01/2023 Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.

D'Angelo E, Espinosa I, Felicioni L, Buttitta F, Prat J. Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.. HUMAN PATHOLOGY. 2023; 141DOI:10.1016/j.humpath.2023.08.010. PMID:37673346. IF:2.700(Q2/4D).

01/11/2025 Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study

Sepulveda, ZV, Tous, S, Quiros, B, Pena, GP, Castro, JB, Serrahima, MP, Galiana, IL, Marí, A, Brunet, A, Bermejo, JO, Cirauqui, BC, Diez, AF, Leon, X, Sumarroca, A, Giner, M, Clavero, O, Goma, M, Pavon, MA, Alemany, L, Bernal, MO. Circulating tumor DNA (ctDNA) for minimal disease detection in oropharyngeal cancer (OPC): results from the CAPTION Spanish prospective study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2028. PMID:. IF:65.400(Q1/1D).

01/12/2023 Diagnostic Efficacy of High-Resolution Computed Tomography Densitometry for Diagnosing Otosclerosis.

Puiggrós IV, Moreno EG, Dotu CO, Agustí MQI, Díaz FL. Diagnostic Efficacy of High-Resolution Computed Tomography Densitometry for Diagnosing Otosclerosis.. OTOLOGY & NEUROTOLOGY. 2023; 44(10)DOI:10.1097/MAO.0000000000004012. PMID:37733986. IF:1.900(Q2/3D).

01/11/2023 Second esophageal neoplasms after head and neck index tumor: Incidence, risk factors and prognosis.

Pujol A, Llansana A, Pérez-Ugarte L, Sauter B, Quer M, León X. Second esophageal neoplasms after head and neck index tumor: Incidence, risk factors and prognosis.. Acta Otorrinolaringologica Espanola. 2023; 74(6)DOI:10.1016/j.otoeng.2022.10.009. PMID:37149128. IF:(Q/D).

12/01/2026 Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review

Rodrigo, JP, de Lima-Souza, RA, López, F, Stenman, G, Agaymy, A, Quer, M, Paleri, V, Leivo, I, Nadal, A, Zidar, N, Mariano, FV, Hellquist, H, Gale, N, Ferlito, A. Biomarkers for Predicting Malignant Transformation of Premalignant Lesions of the Larynx: A Systematic Review. Diagnostics. 2026; 16(2)DOI:10.3390/diagnostics16020236. PMID:41594212. IF:3.300(Q1/2D).

01/01/2026 Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus

Villatoro-Sologaistoa, JC, Villatoro-Sologaisto, JC, Casasayas-Plass, M, Martel-Martin, M, Alfonso-Carrillo, C, Armengot-Carceller, M, Dominguez-Sosa, MS, Fernandez-Liesa, R, Garcia-Lliberós, A, Gil-Melcón, M, González-Compta, X, López-Alvarez, F, López-Chacón, M, Lobo-Duro, D, Mata-Castro, N, Monjas-Cánovas, I, Moreno-Luna, R, Pardo-Muñoz, L, Pinilla-Urraca, M, Santamaría-Gadea, A, Santos-Pérez, J, Valcárcel-Martin, F, Villacampa-Aubá, JM, del Cuvillo-Bernal, A, Sánchez-Gómez, S, Massegur-Solench, H, Bernal-Sprekelsen, M, Alobid, I. Standardization of Sinonasal Anatomical Terminology in Spanish: An Expert Consensus. Acta Otorrinolaringologica Espanola. 2026; 77(1)DOI:10.1016/j.otorri.2025.512275. PMID:. IF:(Q/D).

12/02/2024 Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.

Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B, Cervera M, Luzardo H, Hernandez-Rivas JM, Sitges M, Garcia-Cadenas I, Abrisqueta P, Montesinos P, Bastos-Oreiro M, De Llano MQ, Bravo P, Torrent A, Herrera P, Garcia-Guinon A, Vall-Llovera F, Serrano J, Terol MJ, Bergua JM, Garcia-Noblejas A, Barrenetxea C, Llorente L, Garcia-Belmonte D, Gimeno E, Cladera A, Mercadal S, Sancho JM. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial.. HAEMATOLOGICA. 2024; 109(2)DOI:10.3324/haematol.2023.283342. PMID:37560813. IF:10.100(Q1/2D).

15/01/2024 Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.

Piñana JL, Tridello G, Xhaard A, Wendel L, Montoro J, Vazquez L, Heras I, Ljungman P, Mikulska M, Salmenniemi U, Perez A, Kröger N, Cornelissen JJ, Sala E, Martino R, Geurten C, Byrne J, Maertens J, Kerre T, Martin M, Pascual MJ, Yeshurun M, Finke J, Groll AH, Shaw PJ, Blijlevens N, Arcese W, Ganser A, Suarez-Lledo M, Alzahrani M, Choi G, Forcade E, Paviglianiti A, Solano C, Wachowiak J, Zuckerman T, Bader P, Clausen J, Mayer J, Schroyens W, Metafuni E, Knelange N, Averbuch D, de la Camara R. Upper and/or lower respiratory tract infection caused by human metapneumovirus after allogeneic hematopoietic stem cell transplantation.. JOURNAL OF INFECTIOUS DISEASES. 2024; 229(1)DOI:10.1093/infdis/jiad268. PMID:37440459. IF:4.500(Q1/2D).

28/11/2023 Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.

Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik MM, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan EA, Daly A, Dholaria B, Diaz MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi P, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Solh MM, Solomon SR, Ulrickson ML, Ustun C, van der Poel MWM, Verdonck LF, Wagner JL, Wang TP, Wirk B, Zeidan AM, Litzow MR, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: a CIBMTR analysis.. Blood Advances. 2023; 7(22)DOI:10.1182/bloodadvances.2023011308. PMID:37792849. IF:7.400(Q1/2D).

14/11/2023 Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.

Sierra J, Montesinos P, Thomas X, Griskevicius L, Cluzeau T, Caillot D, Legrand O, Minotti C, Luppi M, Farkas F, Bengoudifa BR, Gilotti G, Hodzic S, Rambaldi A, Venditti A. Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial.. Blood Advances. 2023; 7(21)DOI:10.1182/bloodadvances.2023009847. PMID:37581981. IF:7.400(Q1/2D).

01/11/2023 Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.

Rampotas A, Sockel K, Panitsas F, Theuser C, Bornhauser M, Hernani R, Hernandez-Boluda JC, Esquirol A, Avenoso D, Tsirigotis P, Robin M, Czerw T, Helbig G, Roddie C, Lambert J, McLornan DP. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.. Transplantation And Cellular Therapy. 2023; 29(11)DOI:10.1016/j.jtct.2023.08.020. PMID:37633414. IF:3.600(Q1/3D).

02/10/2023 Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.

Baron F, Nagler A, Galimard JE, Sanz J, Versluis J, Forcade E, Chevallier P, Sirvent A, Anthias C, Kuball J, Furst S, Rambaldi A, Sierra J, von dem Borne PA, Gallego Hernanz MP, Cluzeau T, Robinson S, Raiola AM, Labussière-Wallet H, Byrne JL, Malfuson JV, Ruggeri A, Mohty M, Ciceri F. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.. BRITISH JOURNAL OF HAEMATOLOGY. 2023; 204(1)DOI:10.1111/bjh.19130. PMID:37784256. IF:5.100(Q1/2D).

01/10/2023 Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Puertas B, González-Calle V, Sureda A, Moreno MJ, Oriol A, González E, Rosiñol L, López J, Escalante F, Martínez-Lopez J, Carrillo E, Clavero E, Ríos-Tamayo R, Rey-Bua B, González-Rodríguez AP, Dourdil V, De Arriba F, González S, Pérez-de-Oteyza J, Hernández MT, García-Mateo A, Bargay J, Bladé J, Lahuerta JJ, San Miguel JF, Ocio EM, Mateos MV. Randomized phase II study of weekly carfilzomib 70 mg/m(2) and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.. HAEMATOLOGICA. 2023; 108(10)DOI:10.3324/haematol.2022.282490. PMID:37102598. IF:10.100(Q1/2D).

26/09/2023 Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.

Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study.. Blood Advances. 2023; 7(18)DOI:10.1182/bloodadvances.2023010236. PMID:37315225. IF:7.400(Q1/2D).

23/05/2023 Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.

Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault de Latour R, Esquirol A, Michel G, Chevallier P, Rubio MT, Cornelissen JJ, Michallet M, Volt F, Rivera Franco MM, Scigliuolo GM, Cappelli B, Rocha V, Gluckman E. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe.. Blood Advances. 2023; 7(10)DOI:10.1182/bloodadvances.2022007941. PMID:36350759. IF:7.400(Q1/2D).

20/01/2026 Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024

Formigo, GMS, Mazorra, Z, Olexen, C, Menéndez, T, Hadi, LA, Handgretinger, R, Hernandez, AAB, El Najjar, I, Coukos, G, Sabzevari, H, Bollard, C, Couriel, D, Wald, D, Hamieh, M, Briones, J, Al Kaabi, F, Ventura-Carmenate, Y. Cancer immunotherapy insights: key takeaways from the ADSCC bone marrow and cellular therapy congress 2024. Frontiers in Immunology. 2026; 16DOI:10.3389/fimmu.2025.1650023. PMID:41641269. IF:5.900(Q1/2D).

01/01/2026 Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe

Ammar, D, Sanges, C, Henderson, D, Schapitz, I, Hudecek, M, Luu, M, Schüssler-Lenz, M, Buchholz, C, Franz, P, Reiche, K, Köhl, U, Ifrah, N, Quesnel, B, Thermeli, M, Kersten, MJ, Locatelli, F, D'Amore, ML, Bonini, C, Casucci, M, Philippar, U, Doeswijk, R, Thielen, F, Uyl-de Groot, C, Theelen, J, Schröder, B, Kremer, A, Quaranta, M, Prosper, F, Van den Brulle, J, Grawunder, U, Donnadieu, E, Galy, A, Ferrand, C, Worel, N, Busch, D, Briones, J, Sellner, L, Kuball, J, Sureda, A, Awigena-Cook, J. Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in Europe. CYTOTHERAPY. 2026; 28(1)DOI:10.1016/j.jcyt.2025.09.007. PMID:41217312. IF:3.200(Q2/3D).

01/01/2026 HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study

Salas, MQ, Moya, TA, Pasic, I, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Garcia, II, Mussetti, A, Lavilla, E, Lopez-Marin, J, Filaferro, S, Balsalobre, P, Bento, L, Law, A, Viswabandya, A, Michelis, F, Mattsson, J, Alibhai, S, Rovira, M, Kim, DDW, Sured, A, Kumar, R. HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study. Eclinicalmedicine. 2026; 91DOI:10.1016/j.eclinm.2025.103753. PMID:41567713. IF:10.000(Q1/1D).

18/12/2025 Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party

Tomaszewska, A, Basak, GW, Peczynski, C, Polge, E, Ambron, P, Boreland, W, Sica, S, Arat, M, Passweg, J, Lorenzo, JLL, Salmenniemi, U, Jindra, P, Kulagin, A, Bufarull, RM, Eder, M, Bekadja, MA, Mussetti, A, Graham, CE, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Complications of Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-A Prospective Study on Behalf of the EBMT Transplant Complications Working Party. Cancers. 2025; 17(24)DOI:10.3390/cancers17244029. PMID:41463278. IF:4.400(Q2/3D).

01/12/2025 Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group

Alós, DG, Sanchez, S, Dominguez, SR, Magnano, L, Barca, EG, Vicente, FD, Iacoboni, G, Manso, RG, Losada, CM, Huerga, S, Baumann, T, Izquierdo, AR, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Abellan, PF, Sturla, AL, Vidaller, PJP, Amutio, E, Toimil, FS, Pra, AM, Mico, M, De La Mano, EP, De La Cruz, B, Browne, S, Landwehr, M, Hernandez, I, Andreu, R, De La Cruz, J, Ubieto, AJ. Impact of EBV status on the characteristics and prognosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients: Long-term experience from the GELTAMO group. BLOOD. 2025; 146DOI:10.1182/blood-2025-472. PMID:. IF:23.100(Q1/1D).

01/12/2025 Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients

Moya, TA, Gay, MQS, Pasic, I, Gonzalez, MB, Gómez, MA, Salinas, AS, Camacho, JS, Alvaro, VI, Abdallah-Lefdil, Z, Navascues, JC, Gambarte, LP, Fernandez-Luis, S, Vega, L, Villar, S, Murillo, PB, Esquirol, A, Garcia, II, Mussetti, A, Lavilla-Rubira, E, Lopez, J, Filafferro, S, Balsalobre, P, Miguel, LBD, Michelis, F, Viswabandya, A, Mattsson, J, Alibhai, S, Rovira, M, Kim, D, Balari, AS, Kumar, R. Frailty assessed by HCT-FS predicts survival and non-relapse mortality across hematologic disorders undergoing allo-HCT: A multicenter Study of 992 patients. BLOOD. 2025; 146DOI:10.1182/blood-2025-2652. PMID:. IF:23.100(Q1/1D).

01/12/2025 Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis-a randomized prospective european trial

Kroeger, N, Sanz, J, Stelljes, M, Martino, R, Rambaldi, A, Kwon, M, Sanchez-Guijo, F, Markova, M, Bondarenko, S, Eder, M, Heuser, M, Solano, C, Bonifazi, F, Wohlfarth, P, Massoud, R, Ayuk, F, Clausen, J, Choi, G, Greinix, H, Chiusolo, P, Patriarca, F, Gagelmann, N, Busca, A, Bug, G, Schroeder, T, Bethge, W, Glöckner, A, Hoelzer, D, Zey, S, Buchner, H, Wolschke, C. Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis-a randomized prospective european trial. BLOOD. 2025; 146DOI:10.1182/blood-2025-171. PMID:. IF:23.100(Q1/1D).

01/12/2025 Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Westin, J, Chavez, J, Schuster, SJ, Vucinic, V, Young, PA, Johnson, PC, Bramanti, S, Rambaldi, A, Meijide, JB, Kato, K, Sancho, JM, Kwon, M, Solano, C, Fleming, S, Dahiya, S, Garcia-Sancho, AM, Ramos, PM, Pearson, D, Diallo, S, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results. BLOOD. 2025; 146DOI:10.1182/blood-2025-670. PMID:. IF:23.100(Q1/1D).

01/12/2025 Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Barba, P, Rambaldi, A, Boissel, N, Doki, N, Blaise, D, Ciceri, F, Meijide, JB, Kwon, M, Fleming, S, Goñi, CB, Teshima, T, Kato, K, Balsat, M, Jaeger, U, Shune, L, Ramos, PM, Pearson, D, Corcoran, J, Zia, A, Foster, M, Masood, A, Dickinson, M. Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). BLOOD. 2025; 146DOI:10.1182/blood-2025-811. PMID:. IF:23.100(Q1/1D).

28/11/2025 Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC

Munárriz, D, Pérez-Lopez, E, Rodríguez, CM, Luque, M, Esquirol, A, Calvo, CM, Aparicio, C, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lopez-Lorenzo, JL, Fleitas, CA, González-Rodriguez, AP, García, L, Torrado, T, Filaferro, S, Balsalobre, P, Cascon, MJP, Rovira, M, Salas, MQ. Donor age as an independent predictor of inferior outcomes after haploidentical hematopoietic cell transplantation in acute myeloid leukemia. Study conducted on behalf of GETH-TC. Frontiers in Immunology. 2025; 16DOI:10.3389/fimmu.2025.1700463. PMID:41394844. IF:5.900(Q1/2D).

03/11/2025 Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Torres-Esquius, S, Gabarros-Subira, M, Gurnari, C, Bravo-Perez, C, López, GR, Arias, RD, Sanz, A, Martinez, MM, Beas, F, Jáuregui, SN, Arias, R, Canela, MP, Saumell, S, Voso, MT, Maciejewski, J, Acha, P, Valcarcel, D, Jerez, A, Montoro, MJ. Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy. BLOOD. 2025; 146DOI:10.1182/blood-2025-4997. PMID:. IF:23.100(Q1/1D).

03/11/2025 First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO)

Ubieto, AJ, Alós, DG, Dominguez, SR, Magnano, L, Sánchez, S, Vicente, FD, Iacoboni, G, Losada, CM, Manso, RG, Browne, S, Izquierdo, AR, Baumann, T, Bacelar, AG, Santaella, MP, Prieto, PG, De Villambrosia, SG, Bastos-Oreiro, M, Hernandez, AC, De Miguel, LB, Sturla, AL, Abellan, PF, Vidaller, PJP, Amutio, E, Toimil, FS, Pardal, E, Micó, M, Prat, AM, De La Cruz, B, Huerga, S, Landwehr, M, Hernández, I, Andreu, R, De la Cruz, J, Barca, EG. First-line therapy with rituximab vs. rituximab-CHOP in post-transplant monomorphic diffuse large B-cell lymphoma (DLBCL): Long-term real-world evidence from the spanish group of lymphoma (GELTAMO). BLOOD. 2025; 146DOI:10.1182/blood-2025-3677. PMID:. IF:23.100(Q1/1D).

03/11/2025 Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG)

Gurnari, C, Ottone, T, Piciocchi, A, Späth, D, Meid, A, Marsili, G, Fabiani, E, Romano, F, Pascale, MR, Chiusolo, P, Di Ianni, M, Sobas, M, Brunetti, L, Oñate, G, Infante, JB, Nanni, J, Vetro, C, Boada, M, Candoni, A, Sierra, J, Potter, N, Gilkes, A, Johnson, S, Thomas, I, Huntley, B, Russell, N, Dillon, R, Döhner, H, Döhner, K, Voso, MT. Diagnostic evaluation methods and prognostic impact of FLT3-ITD microclones in Acute Myeloid Leukemia (AML): A retrospective multicenter study on behalf of the EHA AML-specialized working group (SWG). BLOOD. 2025; 146DOI:10.1182/blood-2025-217. PMID:. IF:23.100(Q1/1D).

03/11/2025 First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study

Hernández-Rivas, JA, Prat, AM, Ponce, ES, Medina, A, Lluch-García, R, Oliveira, ACD, Rodriguez-Fernandez, A, Soler, JA, Terol-Castera, MJ, Machado-Machado, P, Pérez-Encinas, M, Romero-Carmona, R, Segundo, LYS, García-Martin, P, Mompo, C, Zubillaga-Marban, E. First worldwide real-life data on fixed-duration ibrutinib plus venetoclax treatment for previously untreated CLL/SLL patients: Updated interim analysis of Spain's LI plus VE observational study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2728. PMID:. IF:23.100(Q1/1D).

03/11/2025 Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study

Niebla, AM, Gine, E, Bastos-Oreiro, M, Perez, A, Cabirta, A, Vicente, FD, Vilaseca, MC, Ubieto, AJ, De Villambrosia, SG, Prat, AM, Barca, EG, Henriquez, HDL, Herranz, ER, Prieto, PG, Cordoba, R, Carreres, AS, Garcia-Sancho, AM, Moya, AMGN, Grande, C, Martine, PP, Nicolas, C, Gutierrez, A, Rivas, JAH, Sanchez-Gonzalez, B, Villalobos, MT, Garcia-Cerecedo, T, Trillo, RA, Donato, E, Gutierrez, PV, Belmonte, DG, Cozzarelli, SRV, Ordoñez, SS, De La Mano, EP, Avaría, A, Blanco, LV, Roldan-Perez, A, Sancho, JM, De la Cruz, B, Prince-Eladnani, R, Abrisqueta, P. Characterization and outcomes of patients with indolent Mantle Cell Lymphoma (iMCL) in Spain. the GELTAMO-MCL-2022 Study. BLOOD. 2025; 146DOI:10.1182/blood-2025-3592. PMID:. IF:23.100(Q1/1D).

03/11/2025 Dissecting the heterogeneity of IGHV-mutated CLL: An eric study

Chatzikonstantinou, T, Agathangelidis, A, Talimtzi, P, Laidou, S, Minga, E, Roussos, A, Angelopoulou, M, De Tomas, MA, Antic, D, Baran-Marszak, F, Bödör, C, Albareda, FB, Catherwood, M, Chatzileontiadou, S, Chessa, C, Coscia, M, Crespo, M, Cuneo, A, Davis, Z, Dimou, M, Doubek, M, Efstathopoulou, M, Espinet, B, Gaidano, G, Gupta, R, Hatzimichael, E, Herishanu, Y, Karamanli, T, Konstantinou, E, Kotsianidis, I, Koumpis, AE, Laszlo, T, Levy, V, Machairas, A, Martini, F, Moia, R, Mouhssine, S, Prat, AM, Murru, R, Mpalaoura, E, Pangalis, G, Papaioannou, M, Pavlova, S, Plevova, K, Pospisilova, S, Puiggros, A, Rani, L, Rigolin, GM, Romano, I, Rossi, D, Serna, A, Simkovic, M, Smolej, L, Stavrogianni, N, Vujovic, KT, Trentin, L, Vassilakopoulos, T, Visentin, A, Vitale, C, Vrachiolias, G, Scarfo, L, Chatzidimitriou, A, Ghia, P, Stamatopoulos, K. Dissecting the heterogeneity of IGHV-mutated CLL: An eric study. BLOOD. 2025; 146DOI:10.1182/blood-2025-2120. PMID:. IF:23.100(Q1/1D).

03/11/2025 Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group

Bastos-Oreiro, M, Cabirta, A, Perez, A, Carreres, AS, De Villambrosia, SG, Canelo, M, Moya, AMGN, Benito, BD, Gutiérrez, PV, Vicente, FD, Caballero, JC, Jiménez-Ubieto, A, Belmonte, DG, Prat, AM, Barca, EG, Henríquez, HDL, Herranz, ER, Garcia-Sancho, AM, Grande, C, Nicolás, C, Gutierrez, A, Gomez-Llobell, M, Rivas, JAH, Sánchez-González, B, Campos, AF, Trillo, RA, Donato, E, Cozzarell, SRV, Ordoñez, SS, De La Mano, EP, Prieto, PG, Avaria, A, Blanco, LV, Roldán-Pérez, A, Cordoba, R, Sancho, JM, Gine, E, Garces, VN, Abrisqueta, P, Niebla, AM. Central nervous system involvement in Mantle Cell Lymphoma: A retrospective multicenter cohort study from the spanish geltamo group. BLOOD. 2025; 146DOI:10.1182/blood-2025-3585. PMID:. IF:23.100(Q1/1D).

03/11/2025 Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Gabarros-Subira, M, Torres-Esquius, S, Pomares, H, Beas, F, Suárez-Gonzalez, J, Sanchez, AH, Lopez-Fernandez, E, López, GR, Hermosin-Ramos, M, Carreño, G, Castillo, IM, García, JD, Santiago, M, Pascual, M, Díaz-Beyá, M, Carrascosa, GB, Montoya, RT, Ortuño, FJ, Vives, S, Mañó, LG, Casares, MTG, Alfonso-Pierola, A, Pris-Vilaespesa, M, Revilla, N, Alonso, S, Iborra, A, Lores, BF, Díaz, RMA, Cervera, J, Corral, LL, Canela, MP, Buño, I, Montoro, MJ, Hernandez, F, Albareda, FB, Arnan, M, Valcarcel, D, Martinez-Laperche, C, Jerez, A. Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers. BLOOD. 2025; 146DOI:10.1182/blood-2025-4275. PMID:. IF:23.100(Q1/1D).

01/09/2025 Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

01/09/2025 Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax plus Azacitidine (VEN plus AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations

Wei, AH, Reyner, JE, Garciaz, S, Aldoss, I, Piérola, A, Allred, A, Dominguez, JMA, Barreyro, L, Bories, P, Daskalakis, N, Porta, MGD, Döhner, H, D'Souza, A, Dugan, J, Fathi, A, Fedele, P, Ferrante, L, Kobos, R, Gaj, S, Diaz, AG, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jabbour, E, Trancucci, D, Bamidele, T, Jentzsch, M, Kantarjian, H, Konopleva, M, Krönke, J, Hütter-Krönke, ML, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Morillo, D, O'Nions, J, Packman, K, Papayannidis, C, Récher, C, Roellig, C, Salamero, O, Nagarajahastri, P, Sauer, T, Searle, E, Tovar, N, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Platzbecker, U. Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With Venetoclax plus Azacitidine (VEN plus AZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/ Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

01/09/2025 Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

01/06/2025 Regression of pre-existing white matter hyperintensities after CD19 CAR Tcell induced ICANS: A case series

Borrell-Pichot, M, Lozano, A, Granell, E, Caballero, A, Briones-Mejide, J, Caballero-Avila, M, Vidal-Jordana, A, Querol, L, Mart n-Aguilar, L. Regression of pre-existing white matter hyperintensities after CD19 CAR Tcell induced ICANS: A case series. EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32DOI:. PMID:. IF:3.900(Q1/3D).

01/05/2025 RNA-Seq analysis of the tumor microenvironment reveals prognostic subgroups in Acute Myeloid Leukemia with myelodysplasia-related gene mutations

Cortés-Bullich, A, Guijarro, F, Jiménez-Vicente, C, Bataller, A, Martínez-Roca, A, Triguero, A, Guerra, ML, Castaño-Diez, S, Oñate, G, Díaz-Beyá, M, Pich-Roselló, O, Esteve, J. RNA-Seq analysis of the tumor microenvironment reveals prognostic subgroups in Acute Myeloid Leukemia with myelodysplasia-related gene mutations. ANNALS OF HEMATOLOGY. 2025; 104(1)DOI:. PMID:. IF:2.400(Q2/5D).